Phase I Study of Adoptive Immunotherapy of Refractory Viral Infection with ex vivo Expanded Rapidly Generated Virus Specific T (R-MVST) Cells
Study of R-MVST Cells to Treat Patients with a Viral Infection
Sponsor: CUMC
Enrolling: Male and Female Patients
IRB Number: AAAS9079
U.S. Govt. ID: NCT05183490
Contact: Research Nurse Navigator: 212-342-5162 /
Additional Study Information: The purpose of this study is to test whether giving an experimental cell product can treat viral infection in patients who have conditions that cause the poor function of their immune system. The patients with infections caused by viruses such as cytomegalovirus (CMV), Epstein-Barr virus (EBV), adenovirus (ADV), BK and JC polyomaviruses (PyVs) virus may participate in this study. The cell product is called rapidly generated virus-specific T cells (R-MVST). R-MVST cells will be manufactured in our laboratory at Columbia University Irving Medical Center. This cell product has not been approved by the Food and Drug Administration (FDA).
Pawel Muranski, MD
Do You Qualify?
Are you over the age of 18? Yes No
Have you been diagnosed with a viral infection? Yes No
Have you been treated with a steroid, such as prednisone or an equivalent? Yes No
You may be eligible for this study

Place Holder

For more information, please contact:
Research Nurse Navigator